Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Current Deferred Revenue (2016 - 2025)

Macrogenics (MGNX) has disclosed Current Deferred Revenue for 14 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 33.08% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 33.08% decrease, with the full-year FY2025 number at $10.9 million, down 33.08% from a year prior.
  • Current Deferred Revenue was $10.9 million for Q4 2025 at Macrogenics, up from $10.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $100.0 million in Q1 2023 to a low of $3.5 million in Q1 2021.
  • A 5-year average of $19.6 million and a median of $16.3 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 626.19% in 2022, then tumbled 77.16% in 2024.
  • Macrogenics' Current Deferred Revenue stood at $20.6 million in 2021, then tumbled by 51.62% to $10.0 million in 2022, then surged by 116.77% to $21.7 million in 2023, then decreased by 24.63% to $16.3 million in 2024, then plummeted by 33.08% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Current Deferred Revenue are $10.9 million (Q4 2025), $10.3 million (Q3 2025), and $7.9 million (Q2 2025).